DLL3 and neuroendocrine neoplasm: Other DLL3-targeting TCEs and molecules, including BI 764532, QLS31904, RO7616789, and PT217, have entered phase 1 clinical trials and are being evaluated in patients with DLL3-positive SCLC and other neuroendocrine tumors (NETs; Table 1, Table 2).